No Data
Express News | Aquestive Therapeutics Announces Two Encore Poster Presentations Highlighting Positive PK And PD Data From Clinical Studies For Anaphylm (Epinephrine) Sublingual Film At The Eastern Allergy Conference From May 30 To June 2
With A 27% Price Drop For Aquestive Therapeutics, Inc. (NASDAQ:AQST) You'll Still Get What You Pay For
Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares have retraced a considerable 27% in the last month, reversing a fair amount of their solid recent performance.
CRSP, NYMT and SBRA Are Among After Hour Movers
Aquestive Therapeutics Initiated at Outperform by Leerink Partners
Aquestive Therapeutics Initiated at Outperform by Leerink Partners
Express News | Leerink Partners Initiates Coverage On Aquestive Therapeutics With Outperform Rating, Announces Price Target of $8
Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target
Aquestive Therapeutics (AQST) has an average rating of buy and price targets ranging from $5.50 to $13, according to analysts polled by Capital IQ.
JESSE JAMES8832 : let it get beat down so i can buy it up
Jaguar8OP JESSE JAMES8832: Your wish will be granted
JESSE JAMES8832 Jaguar8OP: at least i get my way somehow llol